Nathan D. Jorgensen - 29 Jan 2024 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Katie Kazem, Attorney-in-Fact
Issuer symbol: VOR
Transactions as of: 29 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 31 Jan 2024, 19:34:33 UTC
Previous filing: 08 Nov 2023
Next filing: 08 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VOR	Common Stock	Award	$0	+50,000	+34%	$0.000000	198,449	29 Jan 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Employee Stock Option (right to buy)	Award	$0	+100,000		$0.000000	100,000	29 Jan 2024	Common Stock	100,000	$2.41	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.
F2	Includes 2,802 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F3	The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.